# Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

> **NCT03071055** · PHASE2 · COMPLETED · sponsor: **Southeast Clinical Research Associates, LLC** · enrollment: 20 (actual)

## Conditions studied

- Exudative Age Related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab Injection [Lucentis]

## Key facts

- **NCT ID:** NCT03071055
- **Lead sponsor:** Southeast Clinical Research Associates, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-01
- **Primary completion:** 2019-06-03
- **Final completion:** 2019-06-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03071055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03071055, "Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03071055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*